Exogenous CD38 upregulation enables high-efficacy dually cascade targeted molecular therapy of leukemia
Bibliographic record
Abstract
No abstract is available for this record. The assistant can identify its topic from the title, but cannot infer the study’s results.
Source: Not provided · Quality: missing
Research context
OpenAlex topics: Advanced biosensing and bioanalysis techniques · RNA Interference and Gene Delivery · Multiple Myeloma Research and Treatments
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
References (52)
Show source-provided references
1. Cancer nanomedicine: progress, challenges and opportunities10.1038/nrc.2016.108 ↗
2. Ligand-installed nanocarriers toward precision therapy
3. Progress and challenges towards targeted delivery of cancer therapeutics10.1038/s41467-018-03705-y ↗
4. Progress, challenges, and future of nanomedicine10.1016/j.nantod.2020.101008 ↗
5. Antibody–drug conjugates for cancer10.1016/S0140-6736(19)31774-X ↗
6. Antibody-drug conjugates in solid tumors: a look into novel targets10.1186/s13045-021-01035-z ↗
7. Targeted drug delivery strategies for precision medicines10.1038/s41578-020-00269-6 ↗
8. First new drug approval for aml in 15 years10.1038/nbt0817-696 ↗
9. Therapeutic vaccination against leukaemia via the sustained release of co-encapsulated anti-PD-1 and a leukaemia-associated antigen10.1038/s41551-020-00624-6 ↗
10. The acute myeloid leukaemia market10.1038/d41573-019-00142-4 ↗
11. FDA-approved ferumoxytol displays anti-leukaemia efficacy against cells with low ferroportin levels10.1038/s41565-019-0406-1 ↗
12. An update of current treatments for adult acute myeloid leukemia10.1182/blood-2015-08-604520 ↗
13. Conjugation of haematopoietic stem cells and platelets decorated with anti-PD-1 antibodies augments anti-leukaemia efficacy10.1038/s41551-018-0310-2 ↗
14. Acute myeloid leukemia cell membrane-coated nanoparticles for cancer vaccination immunotherapy10.1038/s41375-021-01432-w ↗
15. Small molecules, big impact: 20 years of targeted therapy in oncology10.1016/S0140-6736(20)30164-1 ↗
16. An expanded universe of cancer targets10.1016/j.cell.2021.02.020 ↗
17. Precision medicine in myeloid malignancies10.1016/j.semcancer.2021.03.034 ↗
18. Harnessing the benefits of available targeted therapies in acute myeloid leukaemia10.1016/S2352-3026(21)00270-2 ↗
19. Cell cycle proteins as promising targets in cancer therapy10.1038/nrc.2016.138 ↗
20. Multifaceted polo-like kinases: drug targets and antitargets for cancer therapy10.1038/nrd3184 ↗
21. Discovery and development of the polo-like kinase inhibitor volasertib in cancer therapy10.1038/leu.2014.222 ↗
22. T-cell-based immunotherapy of acute myeloid leukemia: current concepts and future developments10.1038/s41375-021-01253-x ↗
23. Advances in the treatment of acute myeloid leukemia: new drugs and new challenges10.1158/2159-8290.CD-19-1011 ↗
24. Acute myeloid leukaemia10.1038/nrdp.2016.10 ↗
25. Anti-CD38 monoclonal antibodies in multiple myeloma: another cook in the kitchen?10.1016/S2352-3026(19)30254-6 ↗
26. CD38 antibodies in multiple myeloma: back to the future10.1182/blood-2017-06-740944 ↗
27. Immune-based therapeutic strategies for acute myeloid leukemia10.3390/cancers14010105 ↗
28. Antibody therapies for acute myeloid leukemia: unconjugated, toxin-conjugated, radio-conjugated and multivalent formats10.3390/jcm8081261 ↗
29. CD38-directed CAR-T cell therapy: a novel immunotherapy strategy for relapsed acute myeloid leukemia after allogeneic hematopoietic stem cell transplantation10.1186/s13045-021-01092-4 ↗
30. CD38 knockout natural killer cells expressing an affinity optimized CD38 chimeric antigen receptor successfully target acute myeloid leukemia with reduced effector cell fratricide10.3324/haematol.2020.271908 ↗
31. CD38 as a therapeutic target for adult acute myeloid leukemia and T-cell acute lymphoblastic leukemia10.3324/haematol.2018.192757 ↗
32. Anti-leukemic effects of all-trans retinoic acid in combination with daratumumab in acute myeloid leukemia10.1093/intimm/dxy040 ↗
33. Upregulation of CD38 expression on multiple myeloma cells by all-trans retinoic acid improves the efficacy of daratumumab10.1038/leu.2015.123 ↗
34. Daratumumab immunopolymersome-enabled safe and CD38-targeted chemotherapy and depletion of multiple myeloma10.1002/adma.202007787 ↗
35. GE11 peptide-installed chimaeric polymersomes tailor-made for high-efficiency EGFR-targeted protein therapy of orthotopic hepatocellular carcinoma10.1016/j.actbio.2020.06.020 ↗
36. Ros-responsive polymeric micelles for triggered simultaneous delivery of PLK1 inhibitor/mir-34a and effective synergistic therapy in pancreatic cancer10.1021/acsami.9b02756 ↗
37. Brain delivery of Plk1 inhibitor via chimaeric polypeptide polymersomes for safe and superb treatment of orthotopic glioblastoma10.1016/j.jconrel.2020.10.043 ↗
38. Development of a nanoparticle-based immunotherapy targeting PD-L1 and PLK1 for lung cancer treatment10.1038/s41467-022-31926-9 ↗
39. Challenges and advances in chimeric antigen receptor therapy for acute myeloid leukemia10.3390/cancers14030497 ↗
40. Recent developments in immunotherapy of acute myeloid leukemia10.1186/s13045-017-0505-0 ↗
41. All-trans retinoic acid enhances cytotoxic effect of T cells with an anti-CD38 chimeric antigen receptor in acute myeloid leukemia10.1038/cti.2016.73 ↗
42. Spotlight on volasertib: preclinical and clinical evaluation of a promising Plk1 inhibitor10.1002/med.21392 ↗
43. Synergistic activity of BET inhibitor BI 894999 with PLK inhibitor volasertib in AML in vitro and in vivo10.1016/j.canlet.2018.02.018 ↗
44. Proteasome inhibitors induce FLT3-ITD degradation through autophagy in AML cells10.1182/blood-2015-05-646497 ↗
45. The combination of CUDC-907 and gilteritinib shows promising in vitro and in vivo antileukemic activity against FLT3-ITD AML10.1038/s41408-021-00502-7 ↗
46. A6 peptide-tagged, ultra-small and reduction-sensitive polymersomal vincristine sulfate as a smart and specific treatment for CD44+ acute myeloid leukemia10.1016/j.jconrel.2020.10.005 ↗
47. Critical role of lama4 for hematopoiesis regeneration and acute myeloid leukemia progression10.1182/blood.2021011510 ↗
48. Dysregulated haematopoietic stem cell behaviour in myeloid leukaemogenesis10.1038/s41568-020-0260-3 ↗
49. Fe3O4@Pt nanozymes combining with CXCR4 antagonists to synergistically treat acute myeloid leukemia10.1016/j.nantod.2021.101106 ↗
50. A carboxyl-terminated dendrimer enables osteolytic lesion targeting and photothermal ablation of malignant bone tumors10.1021/acsami.8b15827 ↗
51. Bone morphogenetic protein receptor 1α promotes osteolytic lesion of oral squamous cell carcinoma by SHH-dependent osteoclastogenesis10.1111/cas.15330 ↗
52. Metastasis to bone: causes, consequences and therapeutic opportunities10.1038/nrc867 ↗